Hitting the Target: T2T Therapy in SLE Treat-to-target strategies are not a new concept in rheumatology. It has shown to improve patient outcomes and quality of life in rheumatoid arthritis and psoriatic arthritis and is now being increasingly adopted not only in SLE research https://t.co/PfnG0AeJsH

RheumNow Podcast – Ro, Ro, Ro52 (9.12.2025) Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.Are there benefits to diet or vegan diets? What's the effect of menopause on CTD? Ro52 makes a big entrance with all our ILD coverage this month. https://t.co/T68Cprogm3

There is no criteria for infection-induced Antiphospholipid syndr (APS). aPL & aCL abs have been reported w/ COVID, HCV, HIV, EBV, varicella-zoster, & CMV. infections may induce transient aPL positivity without over APS, but may precipitate APS or catastrophic APS (CAPS).

Definitions for Interstitial Lung Disease: A Consensusfrom the Fleischner Society https://t.co/gEqmkdJLDh https://t.co/8nnWKbKjk9

Call to Update the Classification Criteria in Idiopathic Inflammatory Myopathies (IMM), Why? - EULAR/ACR myositis criteria dont cover specific myositis subtypes - Polymyositis is rare - antisynthetase & necrotizing myopathy & Jo1 Dz not well represented - Need to include MSA, https://t.co/LUfF0VCeJ7

My article 👇 summarizing the 2025 update of EULAR recommendations by @eular_org, presented by Josef Smolen at @APLAR_org https://t.co/QFWZmqm6IR @RheumNow #APLAR25 https://t.co/ctQdu8gQEO

GCs have potent anti-inflammatory effects but it’s long term complications can be catastrophic. In SLE pts, it shows a 3-fold increased risk of organ damage for each addtl 1mg of Pred/day. 📌Aim for short duration of use with lowest effective dose @RheumNow #APLAR25 https://t.co/UugrcX073Z

A self learning program to train non Rheumatologists to interpret pelvic X-rays and identify sacro-iliitis? It works, but it seems the participants were already well trained as pre test scores were already reaching 60+% Surprised to see radiologists constituting 1/4 of the test https://t.co/mRcFRSuAws

PsO/PsA patients have an ⬆️ CV risk brought about by traditional and CV risk factors. Do you perform regular CV risk screening in your patients? @RheumNow #APLAR25 https://t.co/BGNKrKeLsI

IL-17is demonstrate efficacy in SpA tx Comparable with TNFis & JAKis in terms of achieving ASAS40 response rates IL-17is are generally well-tolerated w/⬇️TB risk (very important tx consideration esp in Asia) But watch out for candidal infx, IBD exacerbation @RheumNow #APLAR25 https://t.co/rSUJlZOhKV